Loading clinical trials...
Loading clinical trials...
MEK114375: A Rollover Study to Provide Continued Treatment With GSK1120212 to Subjects With Solid Tumors or Leukemia
Conditions
Interventions
GSK1120212
Docetaxel + GSK1120212
+6 more
Locations
19
United States
Novartis Investigative Site
Goodyear, Arizona, United States
Novartis Investigative Site
Scottsdale, Arizona, United States
Novartis Investigative Site
Sacramento, California, United States
Novartis Investigative Site
Aurora, Colorado, United States
Novartis Investigative Site
New Haven, Connecticut, United States
Novartis Investigative Site
Sarasota, Florida, United States
Start Date
November 2, 2010
Primary Completion Date
January 18, 2018
Completion Date
January 18, 2018
Last Updated
February 19, 2019
NCT05245812
NCT06066138
NCT05039801
NCT05053971
NCT05372640
NCT06498635
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions